丙型肝炎病毒治疗对美国丙型肝炎病毒感染患者非肝癌风险的影响
在美国MarketScan数据库2005年1月至2016年12月的一项回顾性队列研究中,62078例新诊断HCV感染患者中17302例(28%)启动HCV治疗,其中15322例完成8-16周最低有效治疗。启动治疗者发生非肝癌的风险较未治疗者降低11%(HR=0.89,95%CI=0.82-0.96),完成最低有效治疗者降低幅度略高(HR=0.87,95%CI=0.80-0.95)。
要点
- 启动HCV治疗者非肝癌风险较未治疗者降低11%(HR=0.89,95%CI=0.82-0.96)。
- 完成最低有效治疗者非肝癌风险降低略高(HR=0.87,95%CI=0.80-0.95)。
- 胰腺癌、肺癌及双药HCV治疗亚型中关联保持一致。
核心结论
- HCV治疗可显著降低HCV感染患者非肝癌的发病率。
- 尽管癌症或HCV治疗亚型间存在差异,作者认为治疗HCV感染可减轻慢性HCV感染相关的肝外癌症负担。
研究设计与样本
- 回顾性队列研究,使用MarketScan数据库2005年1月至2016年12月数据。
- 纳入62078例新诊断HCV感染患者,17302例(28%)启动HCV治疗,其中15322例完成8-16周最低有效治疗。
- 采用多变量、时变Cox比例风险模型计算治疗与未治疗HCV感染患者发生非肝癌的风险比(HR)。
- 按性别、年龄及是否存在肝硬化或糖尿病进行亚组分析。
主要发现
- 启动HCV治疗者发生非肝癌的风险较未治疗者降低11%(HR=0.89,95%CI=0.82-0.96)。
- 完成最低有效治疗者非肝癌风险降低幅度略高(HR=0.87,95%CI=0.80-0.95)。
- 在完成最低有效治疗者的多数亚组分析中观察到该关联,包括肝硬化患者。
- 按癌症或治疗亚型分层后,胰腺癌、肺癌及双药HCV治疗中关联保持一致。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatitis C virus (HCV) infection is associated with with an increased risk of non-hepatic cancers, but the impact of HCV treatment on non-hepatic cancer is unclear. AIMS: To assess if HCV treatment reduced the incidence of non-hepatic cancers among patients with chronic HCV infection in the US. METHODS: We conducted a retrospective cohort study in MarketScan Databases from January 2005 to December 2016. Multivariable, time-varying Cox proportional-hazards models were used to determine hazard ratios (HRs) of incident non-hepatic cancers in treated and untreated patients with HCV infection. We conduscted subgroup analyses for sex, age, and presence of cirrhosis or diabetes. RESULTS: Among 62 078 patients with newly diagnosed HCV infection, 17 302 (28%) initiated HCV treatment, among whom 15 322 completed 8-16 weeks treatment (minimally effective treatment). Patients who initiated HCV treatment had an 11% decreased risk of developing an incident non-hepatic cancer compared to untreated patients (HR = 0.89, 95% confidence interval (Cl) = 0.82-0.96). The reduction was slightly higher when patients completed a minimally effective treatment (HR = 0.87; 95% Cl = 0.80 - 0.95). This was observed in most subgroup analyses for those who had a minimally effective treatment including patients with cirrhosis. When we stratified cancer or therapy subtypes, the association remained consistent for pancreatic and lung cancers, and dual HCV therapy. CONCLUSIONS: HCV treatment led to a significantly reduced incidence of non-hepatic cancers among patients with HCV infection. Despite discrepancies between cancer or HCV therapy subtypes, our findings suggest that treating HCV infection can decrease the extrahepatic cancer burden associated with chronic HCV infection.
引用
- Wang W, Lo Re V, Guo Y, et al. Impact of hepatitis C virus treatment on the risk of non-hepatic cancers among hepatitis C virus-infected patients in the US. Aliment Pharmacol Ther. 2020. PMID: 32931606. doi:10.1111/apt.16081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。